HLTX-1
HLTX-1 is a pan-coronavirus antiviral
We recently published in Science Magazine that the SARS-CoV-2 spike protein is driven to non-infectious, locked conformation by nanomolar concentrations of free fatty acid. We used cutting edge techniques in structural biology, computational chemistry, biophysical and biochemical methods to discover and validate a novel pan-coronavirus antiviral.
The drug binding pocket and antiviral mechanism is fully conserved in :
- SARS1 (2003), MERS (2012) and SARS-CoV-2 (2019)
- All Variants of Concern (VOC) Alpha, Beta, Delta, Omicron
Unmet Need
There is no home therapeutic treatment for SARS-CoV-2 infection, and similarly no prophylactic treatment for high risk individuals (elderly, disease preconditions, track and trace “proximity positive” individuals, family members of positive cases).
Our vision is to solve this urgent unmet medical need by providing over the counter antivirals which can be applied by infected patients by themselves, at home.
